Refractory neurological diseases, such as Parkinson's disease and fibromyalgia, may progress and become more severe due to multiple factors triggered by alterations in different neural types. Research on disease mechanisms using human iPS cells has allowed us to infer integrated neural cell fragility by inducing differentiation from one iPS cell to different neural subtypes and observing the intracellular changes caused by the disease. On the other hand, based on information obtained from studies on human iPS cells, tailor-made disease model mice can be produced, and an in vivo analysis of pathophysiological phenotypes can be achieved through the use of “reverse-translational neuroscience research”. Hopefully, the development of pharmacological therapeutic approaches using these cell-specific genetically modified disease model animals will lead to tailor-made drug therapies that will be able to control disease onset and intractability. With these research efforts, I intend to perform “reverse-translational neuroscience research” through the integrated analysis of disease iPS cell differentiation-induced cells and would like to contribute to the development of the pharmacology field.